LabelDose · Peptide watch · Evidence grades · How we work Peptide Radar Independent evidence & regulation tracking for men's performance and longevity peptides.
Independent evidence aggregator. Not a clinic, not medical advice.
GUIDE
FDA July 2026 Peptide Review: what the PCAC meeting covers The FDA Pharmacy Compounding Advisory Committee met July 23-24, 2026 to review several peptides nominated for the 503A compounding list. Staff briefing documents proposed NOT adding most of them.
GUIDE
Peptides vs GLP-1: why the comparison is mostly wrong GLP-1 drugs are approved medicines with defined labels and large trials. Most marketed performance peptides are experimental compounds with weak human data. The demand is analogous; the legal and evidence status is not.
RECOVERY & INFLAMMATION
BPC-157: evidence, claims & regulatory status A synthetic 15-amino-acid peptide marketed for gut, tendon and injury recovery. Human evidence is minimal; the FDA staff briefing proposed not adding it to the 503A compounding list.
RECOVERY & INFLAMMATION
TB-500: evidence, claims & regulatory status A synthetic fragment of thymosin beta-4 marketed for tissue repair and recovery. FDA did not identify human administration data; injectable-route risks were flagged.
METABOLIC HEALTH & ENERGY
MOTS-c: evidence, claims & regulatory status A 16-amino-acid mitochondrial-derived peptide tied to metabolism and longevity narratives. FDA found the nomination lacked sufficient information for several uses.
RECOVERY & INFLAMMATION
KPV: evidence, claims & regulatory status A tripeptide related to alpha-MSH fragments, marketed for anti-inflammatory and skin/gut uses. FDA found no human safety/effectiveness information and proposed not adding it.
COGNITIVE PERFORMANCE
Semax: evidence, claims & regulatory status An ACTH-fragment-related heptapeptide marketed as a nootropic. FDA raised characterization, formulation, and effectiveness concerns and proposed not adding it.
LONGEVITY & SLEEP
Epitalon: evidence, claims & regulatory status A synthetic tetrapeptide linked to longevity and telomere marketing. FDA noted a lack of human safety/effectiveness support and proposed not adding it.
LONGEVITY & SLEEP
DSIP / Emideltide: evidence, claims & regulatory status A nonapeptide marketed for sleep and recovery. FDA noted safety/effectiveness gaps and available approved therapies, and proposed not adding it.
COMPARE
BPC-157 vs TB-500: how the evidence compares Both are marketed for recovery and frequently stacked. Both are largely preclinical, both were reviewed by the FDA July 2026 committee, and neither has robust human trials.
Get the regulation & evidence watchlist One email when regulatory status changes or strong new evidence lands. Health topics only. Unsubscribe anytime.
Educational information only. Not medical advice, not a diagnosis, and not an offer to sell any product. These are experimental or unapproved substances; we do not provide dosage, sourcing, or use guidance. Consult a licensed clinician. We link to official sources only.